News | October 16, 2012

Proteon Begins Enrollment in Study of PRT-201 in PAD Patients

Preclinical evidence supporting this Phase I research to be presented at TCT meeting

October 16, 2012 — Proteon Therapeutics Inc. has initiated enrollment in a Phase 1 clinical study of its lead product, PRT-201, in patients with symptomatic peripheral artery disease (PAD) of the superficial femoral or popliteal artery. The open-label Phase 1 dose escalation study will enroll up to 16 patients being treated with balloon angioplasty. Immediately following angioplasty, PRT-201 will be delivered to the arterial wall using the Mercator MedSystems Bullfrog micro-infusion catheter. The primary endpoint of the study will be safety, and efficacy endpoints will be evaluated as well.

"Current treatments of PAD, such as balloon angioplasty and stenting, are associated with unacceptably high rates of restenosis. Treatment with PRT-201 following balloon angioplasty is a novel approach that may prolong patency while avoiding the need for stent implantation," said Chris Owens, M.D., assistant professor of surgery in the Division of Vascular and Endovascular Surgery at the University of California San Francisco, who is the principal investigator for the study.

The clinical trial follows successful preclinical studies demonstrating the potential of PRT-201 to enhance revascularization outcomes in patients suffering from PAD. Proteon will be presenting two posters at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. Abstracts TCT-159 and TCT-160, which provide results from ex vivo studies of PRT-201 treatment of human atherosclerotic arteries, will be presented Tues., Oct. 23, from 8 to 10 a.m.

"Our lead product, PRT-201, represents a highly innovative approach to addressing the significant challenges associated with treating PAD. We believe that local catheter delivery of PRT-201, immediately following balloon angioplasty, could potentially reduce the incidence of restenosis in PAD, resulting in improved outcomes and fewer interventions," said Timothy P. Noyes, president and CEO of Proteon.

This is the fourth clinical study evaluating PRT-201's ability to improve vascular outcomes. Proteon previously completed enrollment in three clinical studies evaluating topical delivery of PRT-201 immediately following surgical creation of an arteriovenous fistula (AVF) or arteriovenous graft (AVG) in patients with chronic kidney disease preparing for or on hemodialysis. Data from Proteon's 150-patient Phase 2 AVF study and 89-patient Phase 1/2 AVG study are expected in early 2013.

For more information: www.proteontherapeutics.com

Related Content

Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic Launches Concerto 3-D Detachable Coil System
News | Embolization devices| October 16, 2017
October 16, 2017 — Medtronic announced the launch of the Concerto 3-D Detachable Coil System at the Cardiovascular an
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
TherOx Gains FDA PMA Approval for SSO2 Therapy System
Technology | Cath Lab| September 29, 2017
September 29, 2017 — TherOx Inc. announced that the U.S.
Overlay Init